10.93
-0.04(-0.36%)
Currency In USD
| Previous Close | 10.97 |
| Open | 11.3 |
| Day High | 11.3 |
| Day Low | 10.87 |
| 52-Week High | 16.5 |
| 52-Week Low | 8.06 |
| Volume | 21,389 |
| Average Volume | 54,154 |
| Market Cap | 148.98M |
| PE | -7.98 |
| EPS | -1.37 |
| Moving Average 50 Days | 11.23 |
| Moving Average 200 Days | 11.28 |
| Change | -0.04 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $2,186 as of September 08, 2025 at a share price of $10.93. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $1,166.49 as of September 08, 2025 at a share price of $10.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
GlobeNewswire Inc.
Aug 20, 2025 1:25 PM GMT
STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
GlobeNewswire Inc.
Aug 19, 2025 10:00 AM GMT
STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
GlobeNewswire Inc.
Aug 13, 2025 10:00 AM GMT
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno